Hilda Mekelenkamp
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hilda Mekelenkamp has a total of 147 co-authors. Here are the top co-authors by number of shared publications:
- Michelle Kenyon
Department of Haematology, King’s College Hospital NHS Foundation Trust, London, UK
7 shared publications - Annalisa Ruggeri
IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Haematology and Bone Marrow Transplantation, Milano, Italy
4 shared publications - Isabel Sánchez-Ortega
EBMT Chief Medical Officer, Executive Office, Barcelona, Spain
4 shared publications - Raffaella Greco
Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Hospital, Milan, Italy
4 shared publications - Anna Sureda
Clinical Hematology Department, Institut Català d’Oncologia-Hospitalet, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain
3 shared publications - Antonio Maria Risitiano
Hematology and Hematopoietic Transplant Unit, Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati (A.O.R.N. Giuseppe Moscati), Avellino, Italy
3 shared publications
Latest Publications
- Open Access
- 16 October 2026
- Published by Wiley in British Journal of Haematology
Paediatric haematopoietic stem cell transplantation research priorities: Results from an international multi‐stakeholder priority setting partnership
Summary: Co‐designed research in paediatric HSCT is limited. We sought to determine research priorities which represent the shared priorities of patients, parents, carers and healthcare professionals (HCP) within Australia, New Zealand, the Netherlands and the United Kingdom. An international, multiphase priority‐setting methodology was implemented in partnership with the James Lind Alliance and delivered over an 18‐month period. Part 1: an international scoping survey asked respondents to submit their research uncertainties related to paediatric HSCT. Part 2: summarising and evidence‐checking the submitted uncertainties. Part 3: interim prioritisation survey. Part 4: consensus workshop. In the first international scoping survey, 667 topic ideas were suggested (45% by consumers, 55% by HCP), which were categorised into 80 summary questions. After systematic literature review, 35 summary questions were judged to be true uncertainties (i.e. not answered by existing evidence). These 35 uncertainties were included in a second interim prioritisation survey and completed by 224 participants. From those, a shortlist of 19 questions was drawn. After a multistakeholder workshop, consensus was reached on the top 10 priorities. The PSP identified important research gaps in the management of paediatric HSCT. Priority areas included: implementing personalised medicine approaches, improving immune recovery and adjunct interventions such as exercise, nutrition and microbiome‐directed strategies.
- 16 October 2026
- Published by Wiley in British Journal of Haematology
Open AccessPaediatric haematopoietic stem cell transplantation research priorities: Results from an international multi‐stakeholder priority setting partnership
Summary: Co‐designed research in paediatric HSCT is limited. We sought to determine research priorities which represent the shared priorities of patients, parents, carers and healthcare professionals (HCP) within Australia, New Zealand, the Netherlands and the United Kingdom. An international, multiphase priority‐setting methodology was implemented in partnership with the James Lind Alliance and delivered over an 18‐month period. Part 1: an international scoping survey asked respondents to submit their research uncertainties related to paediatric HSCT. Part 2: summarising and evidence‐checking the submitted uncertainties. Part 3: interim prioritisation survey. Part 4: consensus workshop. In the first international scoping survey, 667 topic ideas were suggested (45% by consumers, 55% by HCP), which were categorised into 80 summary questions. After systematic literature review, 35 summary questions were judged to be true uncertainties (i.e. not answered by existing evidence). These 35 uncertainties were included in a second interim prioritisation survey and completed by 224 participants. From those, a shortlist of 19 questions was drawn. After a multistakeholder workshop, consensus was reached on the top 10 priorities. The PSP identified important research gaps in the management of paediatric HSCT. Priority areas included: implementing personalised medicine approaches, improving immune recovery and adjunct interventions such as exercise, nutrition and microbiome‐directed strategies.
- 15 October 2026
- Published by Springer Nature in TVZ - Verpleegkunde in Praktijk En Wetenschap
- Vol. 136 (5) , 25-27
Verpleegkundige taal in ontwikkeling
- 15 October 2026
- Published by Springer Nature in TVZ - Verpleegkunde in Praktijk En Wetenschap
- Vol. 136 (5) , 25-27
Verpleegkundige taal in ontwikkeling
- Open Access
- 12 October 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (11) , 1586
Publisher Correction: defining global priorities in hematopoietic transplantation and cellular therapy: a statement paper from the EBMT global committee
- 12 October 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (11) , 1586
Open AccessPublisher Correction: defining global priorities in hematopoietic transplantation and cellular therapy: a statement paper from the EBMT global committee
- Open Access
- 11 August 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (11) , 1475-1479
Defining global priorities in hematopoietic transplantation and cellular therapy: a statement paper from EBMT Global Committee
Hematopoietic cell transplantation, cellular and gene therapies, and (CAR)-T cells have revolutionized outcomes in hematologic disorders. However, major disparities persist in their availability, accessibility, and affordability, particularly in low- and middle-income countries (LMICs). The EBMT Global Committee aims to address these inequalities. A structured survey was distributed to EBMT members to identify regional and thematic priorities, assess current infrastructure, and assess willingness to contribute to global initiatives. Responses were analyzed descriptively and served as the basis for the current statement paper. A total of 145 responses from 43 countries were collected. Most respondents (67.1%) reported working in JACIE- or FACT-accredited centers. The highest priority regions for EBMT outreach were Eastern Europe (non-EU) (43.9%), Latin America (38.2%), and Africa (33.5%), followed by the Middle East (29.5%). The leading thematic priorities were education and training (74.3%), scientific collaboration (56.0%), and registry development (43.4%). Most respondents expressed willingness to actively contribute, particularly in educational activities (59.7%). Qualitative responses emphasized the need for practical guidelines, mentorship programs, telemedicine, virtual discussion/clinical rounds on difficult cases, and support for LMIC capacity building. The EBMT community strongly supports an expanded global role focused on education, capacity building, and collaboration in underserved regions.
- 11 August 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (11) , 1475-1479
Open AccessDefining global priorities in hematopoietic transplantation and cellular therapy: a statement paper from EBMT Global Committee
Hematopoietic cell transplantation, cellular and gene therapies, and (CAR)-T cells have revolutionized outcomes in hematologic disorders. However, major disparities persist in their availability, accessibility, and affordability, particularly in low- and middle-income countries (LMICs). The EBMT Global Committee aims to address these inequalities. A structured survey was distributed to EBMT members to identify regional and thematic priorities, assess current infrastructure, and assess willingness to contribute to global initiatives. Responses were analyzed descriptively and served as the basis for the current statement paper. A total of 145 responses from 43 countries were collected. Most respondents (67.1%) reported working in JACIE- or FACT-accredited centers. The highest priority regions for EBMT outreach were Eastern Europe (non-EU) (43.9%), Latin America (38.2%), and Africa (33.5%), followed by the Middle East (29.5%). The leading thematic priorities were education and training (74.3%), scientific collaboration (56.0%), and registry development (43.4%). Most respondents expressed willingness to actively contribute, particularly in educational activities (59.7%). Qualitative responses emphasized the need for practical guidelines, mentorship programs, telemedicine, virtual discussion/clinical rounds on difficult cases, and support for LMIC capacity building. The EBMT community strongly supports an expanded global role focused on education, capacity building, and collaboration in underserved regions.
- Top Cited PapersOpen Access
- 9 September 2025
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 60 (11) , 1499-1525
Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations
For over two decades, the EBMT has updated recommendations on indications for haematopoietic cell transplantation (HCT) practice based on clinical and scientific developments in the field. This is the ninth special EBMT report on indications for HCT for haematological diseases, solid tumours and immune disorders. Our aim is to provide guidance on HCT indications according to prevailing clinical practice in EBMT countries and centres. In order to inform patient decisions, these recommendations must be considered with the risk of the disease, risk of HCT procedure and non-HCT strategies, including evolving cellular therapies, and their availability on site. HCT techniques are constantly evolving and we make no specific recommendations, but encourage harmonisation of practice, where possible, to ensure experience across indications can be meaningfully aggregated via registry outputs. We also recommend working according to JACIE certification standards to maintain quality in clinical and laboratory practice, including benchmarking of survival outcomes [1,2,3]. Since the last edition, innovative cellular and gene therapies have entered in activity across indications affecting clinical decision making. As the number and type of regulatory authority-approved cellular therapies grow, recommendations for best practice and quality of patient care were developed to support clinicians and will be regularly updated.
- 9 September 2025
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 60 (11) , 1499-1525
Top Cited PapersOpen AccessIndications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations
For over two decades, the EBMT has updated recommendations on indications for haematopoietic cell transplantation (HCT) practice based on clinical and scientific developments in the field. This is the ninth special EBMT report on indications for HCT for haematological diseases, solid tumours and immune disorders. Our aim is to provide guidance on HCT indications according to prevailing clinical practice in EBMT countries and centres. In order to inform patient decisions, these recommendations must be considered with the risk of the disease, risk of HCT procedure and non-HCT strategies, including evolving cellular therapies, and their availability on site. HCT techniques are constantly evolving and we make no specific recommendations, but encourage harmonisation of practice, where possible, to ensure experience across indications can be meaningfully aggregated via registry outputs. We also recommend working according to JACIE certification standards to maintain quality in clinical and laboratory practice, including benchmarking of survival outcomes [1,2,3]. Since the last edition, innovative cellular and gene therapies have entered in activity across indications affecting clinical decision making. As the number and type of regulatory authority-approved cellular therapies grow, recommendations for best practice and quality of patient care were developed to support clinicians and will be regularly updated.
- Open Access
- 11 December 2023
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (3) , e30808
Hoping for a normal life: Decision‐making on hematopoietic stem cell transplantation by patients with a hemoglobinopathy and their caregivers
Background: To provide insight into the perspectives of children and young adults with transfusion‐dependent thalassemia and sickle cell disease and their caregivers regarding the decision for hematopoietic stem cell transplantation (HSCT).Procedure: A qualitative longitudinal multicenter study. Data collection consisted of 40 audio‐recorded conversations between physicians and families and 77 interviews with patients and/or caregivers related to 27 unique cases, collected at different time points throughout the decision‐making process.Results: Conversations and interviews revealed “hoping for a normal life” as an overarching theme, consisting of four main topics: (i) “Building a frame of reference” refers to a process where patients or families try to obtain comprehensive information on HSCT and translate this to their situation to decide. (ii) “Balancing between loss and benefit” reports the process of considering the advantages and disadvantages of continuing with supportive care to treat their disease versus choosing HSCT. (iii) “Experiencing the impact of HSCT” describes the impactfull experience of the HSCT period by those who chose HSCT. (iv) “Balancing again” refers to reflecting on the decision made.Conclusions: The hope for a normal life guided the decision‐making process, described as a constant balance between the impact of the disease and HSCT. A structured approach to explore patients’ and caregivers’ perspectives on HSCT decision‐making is needed, where specifically discussing the impact of the disease and hope for a normal life need to be integrated in the process.
- 11 December 2023
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (3) , e30808
Open AccessHoping for a normal life: Decision‐making on hematopoietic stem cell transplantation by patients with a hemoglobinopathy and their caregivers
Background: To provide insight into the perspectives of children and young adults with transfusion‐dependent thalassemia and sickle cell disease and their caregivers regarding the decision for hematopoietic stem cell transplantation (HSCT).Procedure: A qualitative longitudinal multicenter study. Data collection consisted of 40 audio‐recorded conversations between physicians and families and 77 interviews with patients and/or caregivers related to 27 unique cases, collected at different time points throughout the decision‐making process.Results: Conversations and interviews revealed “hoping for a normal life” as an overarching theme, consisting of four main topics: (i) “Building a frame of reference” refers to a process where patients or families try to obtain comprehensive information on HSCT and translate this to their situation to decide. (ii) “Balancing between loss and benefit” reports the process of considering the advantages and disadvantages of continuing with supportive care to treat their disease versus choosing HSCT. (iii) “Experiencing the impact of HSCT” describes the impactfull experience of the HSCT period by those who chose HSCT. (iv) “Balancing again” refers to reflecting on the decision made.Conclusions: The hope for a normal life guided the decision‐making process, described as a constant balance between the impact of the disease and HSCT. A structured approach to explore patients’ and caregivers’ perspectives on HSCT decision‐making is needed, where specifically discussing the impact of the disease and hope for a normal life need to be integrated in the process.
- Open Access
- 8 April 2023
- Published by Springer Nature
- p. 25-43
HSCT: How Does It Work?
The HSCT (haematopoietic stem cell transplant) is a particular treatment for many haematological and non-haematological diseases. Broadly, there are three different categories of transplantation, autologous, allogeneic and syngeneic, which can be applied to most disease scenarios. Haematopoietic stem cells can be derived from the bone marrow, peripheral blood and umbilical cord blood. HSCT treatment can be divided into separate phases that start with the harvest of the stem cells and passing through the conditioning, aplasia and engraftment until the recovery of the haematopoietic functions. HSCT is indicated in many diseases, and these indications depend on numerous factors such as the disease type, stage and response to previous treatment. This chapter includes transplant in primary immunodeficiency in children, haemoglobinopathies as well as inherited bone marrow failure and inborn errors of metabolism.
- 8 April 2023
- Published by Springer Nature
- p. 25-43
Open AccessHSCT: How Does It Work?
The HSCT (haematopoietic stem cell transplant) is a particular treatment for many haematological and non-haematological diseases. Broadly, there are three different categories of transplantation, autologous, allogeneic and syngeneic, which can be applied to most disease scenarios. Haematopoietic stem cells can be derived from the bone marrow, peripheral blood and umbilical cord blood. HSCT treatment can be divided into separate phases that start with the harvest of the stem cells and passing through the conditioning, aplasia and engraftment until the recovery of the haematopoietic functions. HSCT is indicated in many diseases, and these indications depend on numerous factors such as the disease type, stage and response to previous treatment. This chapter includes transplant in primary immunodeficiency in children, haemoglobinopathies as well as inherited bone marrow failure and inborn errors of metabolism.
- Open Access
- 8 April 2023
- Published by Springer Nature
- p. 155-183
Transplantation Through the Generations
Whilst the basic principles of HSCT remain the same, regardless of the age of the patient, there are a number of important additional considerations relating to transplantation of our younger and older patients and those of adolescent age. The principles outlined in this chapter serve as a valuable reminder supporting age-appropriate patient-centred care delivery. This chapter initially focuses on transplanting the child and its physiological and psycho-social aspects. Subsequently, the nursing challenges in the AYA population will be addressed. This chapter ends with considerations for treatment and care for the older adult.
- 8 April 2023
- Published by Springer Nature
- p. 155-183
Open AccessTransplantation Through the Generations
Whilst the basic principles of HSCT remain the same, regardless of the age of the patient, there are a number of important additional considerations relating to transplantation of our younger and older patients and those of adolescent age. The principles outlined in this chapter serve as a valuable reminder supporting age-appropriate patient-centred care delivery. This chapter initially focuses on transplanting the child and its physiological and psycho-social aspects. Subsequently, the nursing challenges in the AYA population will be addressed. This chapter ends with considerations for treatment and care for the older adult.